12:00 AM
 | 
Jul 01, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

SGI-110: Interim Phase I/II data

Interim data from 15 evaluable intermediate- and high-risk MDS patients who received prior azacitidine or decitabine therapy in the dose-escalation Phase I portion of the open-label, U.S. Phase I/II SGI-110-01 trial showed that subcutaneous SGI-110 led to an overall response rate (ORR) of 40%. Median duration of response was 92 days. The most common adverse event reported was injection site pain and myelosuppression. Data were presented at the European Hematology Association meeting in Stockholm. Additional data...

Read the full 359 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >